Interpace Biosciences IDXG Estimates

OTC IDXG
$6.00 -0.39 (-6.10%)
At close: Oct 2, 2026 · 4:00 PM EDT
Analyst Estimates

Interpace Biosciences, Inc. Revenue Estimates

Periods 16
Next Period Q4 23
Consensus 15.08 M

Analysts expect Interpace Biosciences, Inc. to report revenue of 15.08 M for Q4 23, against a range of 14.22 M to 15.94 M. The most recent reported quarter, Q3 23, came in at 9.08 M, a 33.2% miss against the 13.60 M consensus.

Metric Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25
Reported (Actual) 10.38 M9.35 M8.19 M8.33 M9.83 M11.03 M9.08 M--------
High Estimate 10.09 M10.46 M14.00 M14.28 M12.39 M13.24 M14.06 M15.94 M29.54 M31.22 M26.19 M41.62 M38.34 M38.45 M28.97 M
Low Estimate 8.29 M9.73 M11.54 M11.68 M10.87 M11.25 M13.15 M14.22 M25.47 M28.43 M21.84 M38.26 M33.58 M32.16 M24.58 M
Consensus Estimate 9.19 M10.10 M12.77 M12.98 M11.63 M12.25 M13.60 M15.08 M27.50 M29.82 M24.02 M39.94 M35.96 M35.31 M26.77 M
Analyst Estimates

Interpace Biosciences, Inc. Earnings Per Share (EPS) Estimates

Periods 12
Next Period Q4 23
Consensus 0.56

Analysts expect Interpace Biosciences, Inc. to report earnings per share of 0.56 for Q4 23, against a range of 0.52 to 0.60. The most recent reported quarter, Q3 23, came in at -0.60 , in line with the -0.05 consensus.

Metric Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24
Reported (Actual) -2.60-4.60-1.50-1.650.500.45-0.60-----
High Estimate -3.86-2.45-1.05-0.34-0.89-0.38-0.050.603.154.282.283.05
Low Estimate -4.54-2.95-1.29-0.38-1.07-0.44-0.050.522.953.801.922.81
Consensus Estimate -4.20-2.70-1.17-0.36-0.98-0.41-0.050.563.054.042.102.93

Interpace Biosciences, Inc. Estimates API

Pull Wall Street consensus for Interpace Biosciences, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=IDXG&mode=revenue&api_key=YOUR_API_KEY